PT  - JOURNAL ARTICLE
AU  - Mykola Gumeniuk
AU  - Svitlana Panchuk
TI  - Decametoxine influence on bronchial hyperreactivity in patients with bronchial asthma
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P1832
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P1832.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P1832.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - Background. In vitro 0,02% sol. decametoxine has bactericidal and virucidal action against the main viral and bacterial pathogens of infectious exacerbation of asthma, suggesting its clinical effectiveness in patients with infectious exacerbation of asthma.At the same time, in vivo decametoxine inhalation may enhance bronchial hyperresponsiveness and bronchial obstruction. Therefore, the aim of this study was to evaluate the influence of 0.02% sol. decametoxine on bronchial hyperreactivity in patients with asthma.Methods. Spirography was conducted in 26 patients with bronchial asthma (11 men and 15 women aged from 29 to 63 years) in whom confirmation of obstruction reversibility was performed with an inhaled bronchodilator (salbutamol 400 mcg). Next day respiratory function was evaluated before 0.02% sol. decametoxine inhalation (4 ml via nebulizer) and on 15 min and 45 min after inhalation. To determine the reliability of changes in respiratory function ( FVC, FEV1, FEV1/ FVC ) the difference between their absolute values, the initial data and expressed as a percentage of the proper size was calculated. The results are compared with a range of reproducibility of these indicators. Dynamics studies considered significant (positive or negative), if the shift parameters FVC , FEV1 , FEV1/FVC exceeded their reproducibility.All measurements were performed in the first half of the day on the same apparatus by the same investigator.Results: Respiratory function parameters showed that decametoxine inhalation did not significantly altere respiratory function.Conclusions: Decametoxine inhalation do not affect bronchial hyperreactivity, which allows for the possibility of its use in patients with asthma.